Parkinsonscongress-2018 Market Analysis and Reports | singapore Conference Series

Market Analysis - Parkinsonscongress-2018

Parkinson’s disease market is set to expand from $2.1 billion in 2014 to $3.2 billion by 2021, at a moderate Compound Annual Growth Rate (CAGR) of 5.7 percent, game-changing treatments will not be available for the foreseeable future, according to business intelligence provider GBI Research.

There are around 10 million individuals experiencing Parkinson's infection all around. Parkinson's, as far as its essence, has a higher recurrence in the created nations. In the United States (U.S.), around 60,000 new cases are determined to have Parkinson's, every year. Parkinson's malady is an idiopathic sickness happening because of obscure causes. By and by, just symptomatic medication medicines are accessible in the market. Additionally, these indications are analysed at later stages when the greater part of the dopamine creating cells have lost their capacity. This situation demonstrates a looming requirement for inventive medications.

The worldwide Parkinson's sickness showcase is divided on the premise of medication sort and topography. As per sedate sort, the market is portioned into, advertised and pipeline drugs. The showcased drugs are additionally divided into Levodopa, Dopamine agonists, Apomorphine, Glutamate rival, Anticholinergics, COMT inhibitors and MAO-B inhibitors. Topographically, the market is sectioned crosswise over four locales to be specific North America, Europe, Asia Pacific, and LAMEA.

The market for neurodegenerative confusion medicines can be separated into three portions: dynamic dementia, dynamic dementia with other neurological variations from the norm, and development issue.

Dynamic dementia medicines are relied upon to have an estimation of $7.3 billion out of 2012 and about $11 billion of every 2017, a CAGR of 8.4%.

Medicines for dynamic dementia with other neurological variations from the norm should add up to $537.2 million out of 2012 and $913.7 million out of 2017, a CAGR of 11.2%.

Medicines for development issue are relied upon to be worth $3.2 billion out of 2012 and $4.8 billion out of 2017, a CAGR of 8.3%.

In spite of energizing advances in the treatment of disorders of dementia and development issue amid the previous three years, a total therapeudic treatment or medication item has not been found to date. This is basically because of the diverse idea of the maladies and the way that the majority of their fundamental causes are as yet obscure or being contemplated. Various medication items are in the market; nonetheless, these medications are to a great extent for the symptomatic treatment of these sicknesses. Along these lines, there is an earnest requirement for medications for the neurodegenerative sicknesses influencing a huge number of individuals around the world.

This report will help its perusers:

Pick up a diagram of the present and future qualities of the worldwide markets for medicines for disorders of dementia and development issue

Breakdown incomes by neurodegenerative infection and essential clinical/neurotic component

Survey applications for medications and restorative advancements for disorders of dementia and development issue

Recognize the real players in the business destined to contend well now and into what's to come

Survey patent data pertinent to the business.

 UNIVERSITIES IN SINGAPORE

  • Nanyang Technological University
  • Singapore Management University
  • SIM University
  • Singapore Institute of Technology
  • GlobalNxt University
  • Curtin Singapore
  • James Cook University Singapore
  • University of New South Wales Asia
  • Johns Hopkins in Singapore

Hospitals in Singapore

  • Alexandra Hospital
  • Changi General Hospital
  • Ng Teng Fong General Hospital
  • National University Hospital
  • Khoo Teck Puat Hospital
  • Singapore General Hospital
  • Tan Tock Seng Hospital
  • KK Women's and Children's Hospital

Major Associations around the Globe

  •   Neuropathy Association
  • The brain & behavior research foundation
  • Alzheimer's Association
  • American Academy of Neurology
  • European Neurological Societies
  • World Federation of Neurology
  • Spanish Society of Neurology
  •  Major Neurological Associations in Italy
  • Hilarescere Foundation in Italy
  • Italian MS society in Italy  
  • Southern Clinical Neurological Society
  • ESNR European Society of Neuroradiology
  • Vision sciences society

Around 500 top universities globally working in the field of Neuroscience

  •  Dalhousie University
  • Leiden University- Neither land
  • Temple University USA
  • University Oklahoma
  •  Boston Coll USA
  • Florida International University
  • University California – Davis
  • University Sheffield
  • University Manchester
  • University of Nottingham
  • Cardiff University
  • University of Toronto – Canada
  • Hospitals Associated with Neuroscience Research

All around the globe there are 6000 hospitals working on Neurology

  • Some of them among them are:
  • Johns Hopkins Hospital
  • World Brain Centre Hospital
  • Duke University Hospital
  • Edward Hospital
  • Munson Medical Centre

Parkinson’s congress-2018   invites all the participants from all over the world to attend the parkinsonscongress-2018  conference entitled “Global Experts Meeting on Parkinson’s & Movement Disorders” during May 14-15, 2018 Singapore. This gathering is predominantly will focus the most recent and energizing developments in each range of Parkinson’s research, and it will offer an exceptional opportunity for specialists from all over  the world to meet, network, and distinguish with different scientific interactions.

Parkinson’s disease is a dynamic neurological disorder that influences how the individual moves, including how they talk and compose. This disease is caused by low dopamine levels. Various useful treatments, utilizing therapies (physiotherapy), surgery and medications have recognized neurological disorders and changes in the patient group. People with Parkinson’s disease also experience stiffness and they find abnormality in carrying out the movements as rapidly as before- this is known as bradykinesia.

The Parkinson’s disease market in US is expected to grow at a rate of 5.3% from sales of of $1.1 billion in 2012 to $1.3 billion in 2022. Approximately 1 million adults in Asia are suffering from Parkinson’s disease, from where 60,000 were diagnosed annually. An estimated of 30%-50% of PD patients mainly suffering from depression. United States is in the fourth position in considering the death of people due to Parkinson’s disease. African Americans have the highest death rate of 66.4% followed by whites of 64.6%, Hispanic with 55.4% and Asians with 50.8%. Parkinson’s disease strikes 50% more men than women. The economic burden of Parkinson’s disease on patients and their families in the Asia is about $9.4 billion.

Why to attend:

 It is our great pleasure to welcome you to the “Global Experts Meeting on Parkinson’s & Movement Disorders” during May 14-15, 2018 Singapore.

 The Conference will encourage new discoveries and research by providing a platform for reporting of unique and unusual cases which enhance understanding of disease process, its diagnosis, management and clinic-pathologic correlations. It will provide a podium for wide-ranging aspects of psychological, neurological, molecular, genetic and behavioral pathways underlying addiction, and will focus on novel therapies providing quality care for people with unhealthy alcohol, tobacco, or other drug use and addictive behaviors across a spectrum of clinical settings. It will comprise of opening Keynote lectures by the renowned researcher and noble members working in the field of addiction research and treatment followed by the special workshop and symposium sessions by eminent scholars and therapeutic members for all the three days of the conference.

Target audience: Neurologists, Psychiatrists, Psychologists, Neurosurgeon, Head of the department, Director, Industries, Delegates, Clinical, Community members, Professors, Researchers, Students, Scientists, Nurses.

  • Neurologists and Directors
  • Physicians
  • Neuroscientists
  • Specialists
  • Researchers
  • Professors
  • Industrial Experts
  • Neurosurgeons
  • Psychiatrist
  • Nutritional Scientists
  • Lecturers and Students from Academia in the study of Parkinson disease
  • Students from Academia in the research of Neurology and Neuroscience
  • Therapists